OXB Oxford Biomedica plc

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...

Oxford BioMedica PLC (OXBDF) posted GBP80.2 million in H1 2026 revenue, signed 17 new clients, and reaffirmed full-year guidance of GBP180-200 million despite a GBP7.6 million France site impairment.

Oxford Biomedica (LON:OXB) reported higher first-half revenue and improved operating EBITDA as manufacturing activity increased, while management reiterated its full-year 2026 revenue guidance and longer-term growth targets. Revenue for the six months ended in 2026 rose 10% at constant currency to

Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...

Price targets for Oxford Biomedica have shifted, with examples including moves from 1,170 GBp to 1,140 GBp and then to 900 GBp, alongside new targets such as £9.00, £8.00, 595 GBp and 508 GBp. These changes align with a split analyst view, where some still back the long term potential and others focus more on execution risks and slower revenue conversion after recent results. As you read on, you will see how to track this evolving narrative and what to watch if you follow Oxford Biomedica...